BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-43@pharmaconomics
DTSTAMP:20260707T003510Z
DTSTART;VALUE=DATE:20261031
DTEND;VALUE=DATE:20261101
SUMMARY:SRPT Phase 3 — Eteplirsen
DESCRIPTION:Phase 3 trial results for Eteplirsen in Muscular Dystrophy\, Duchenne are due Oct 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT03992430\n\nTrack it: https://pharmaconomics.com/e/43
URL:https://pharmaconomics.com/e/43
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SRPT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR